Answers are grounded in this paper and cite their sources.
Patients with chronic hepatitis-B-virus (HVB) infection may exhibit significant liver pathology despite alanine aminotransferase (ALT) and HBV-DNA levels below current treatment guideline’s cut-off values. This study evaluated thecandidacy for HBV therapy if baseline histopathological changes were considered. Clinical, biochemical, serological, virological, and histopathological (Metavir Score) data of a cohort of 161 consecutive patients [129 (80.1 %) males, mean ± SD age 35.2 ±11.2 years, 130 (80.7% HBeAgnegative, 149 (90.1 %) genotype D] were collected and analyzed. Our results showed that significant pathology (F≥2 and/or A≥2) and significant fibrosis (F≥2 ± A≥2) were found in 98/161(60.9 %) and 81/161(50.3 %) patients respectively. Based on HBV-DNA (>2000 iu/mL or >20000 iu/mL accordingto HBeAg status) and ALT level >2x40 u/L (the standard cut-off value), only 36/161(22.4 %) patients were candidate for therapy. This increased to 71/161(44.1 %) patients when the new ALT cut-off values (30 u/L for males, and 19 u/L for females) were applied. Relying on either (F≥2 and/or A≥2) or (F≥2±A≥2) increases the treatment candidacy by 62/161(38.5 %) or 45/161(28 %), and further increases the candidacy for treatment by 27/161(16.8 %) or 10/161(6.2 %) patients when standard and new ALT cut-off values are applied respectively. Finally, liver histopathology is more reliable than ALT and HBV-DNA levels in the decision to treat patients with chronic HBV infection.
No takes yet. Share an insight, caveat, or question.
Helmy et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: